Starling OncologyvsThermo Fisher Scientific

STLN and TMO stock compared: price, dividend, valuation and results, from SEC filings.

STLN

Starling Oncology, Inc.

$3.50

Value $346M

-6.67%
STLN's page

TMO

Thermo Fisher Scientific Inc

$700.22

Value $260B

+0.11%
TMO's page

Starling Oncology (STLN) has a market value of $346M and Thermo Fisher Scientific (TMO) $260B. Over the last year, with dividends, STLN moved +2.0% and TMO +19.5%. Dividend yield: STLN none, TMO 0.26%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    STLN$346M

    TMO$260B

    TMO is 752 times STLN

  • Revenue, 12 months

    STLN$620M

    TMO$47.4B

    TMO is 76 times STLN

  • Net income, 12 months

    STLN-$36M

    TMO$7.1B

  • Operating margin

    STLN-3.4%

    TMO17.9%

    21.3 points apart

  • ROIC

    STLN-29.9%

    TMO8.2%

    38.1 points apart

  • P/E

    STLN–

    TMO36.8

  • Dividend yield

    STLN0.0%

    TMO0.3%

    0.3 points apart

  • 5-year return

    STLN-68.1%

    TMO+11.8%

    79.9 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

STLN-68.1%

TMO+11.8%

05010020222023202420252026
Returns by period
PeriodSTLNWith dividendsTMOWith dividends
1 year since November 12, 2025+2.0%Price +2.0%+19.5%Price +19.1%
3 years since November 13, 2023+37.3%+11.1% a yearPrice +37.3%+58.8%+16.7% a yearPrice +57.3%
5 years since November 12, 2021-68.1%-20.4% a yearPrice -68.1%+11.8%+2.3% a yearPrice +10.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

STLNStarling OncologyTMOThermo Fisher Scientific

Valuation

STLNTMO
Valuation
Price$3.50$700.22
Market value$346M$260B
Enterprise value (EV)$382M$295B
P/E–36.8
P/E, 5-year median–32.7
P/B–4.8
EV/EBIT–34.9
Free cash flow yield5.4%2.9%

Results and growth

STLNTMO
Results and growth
Revenue, 12 months$620M$47.4B
Net income, 12 months-$36M$7.1B
Free cash flow, 12 months$19M$7.6B
Earnings per share, 12 months-$0.28$18.96
Revenue growth, year on year27.8%3.9%
Revenue growth a year, past+21.8%over 5 years+6.7%over 5 years
EPS growth a year, past–+2.1%over 5 years

Margins and returns on capital

STLNTMO
Margins and returns on capital
Gross margin––
Operating margin-3.4%17.9%
Net margin-5.7%14.9%
ROIC-29.9%8.2%
ROE–13.4%

Balance sheet

STLNTMO
Balance sheet
Cash$37M$6.1B
Total debt$98M$41.4B
Net debt / EBITDA–3.7
Interest cover-2.8×5.5×

Dividends and buybacks

STLNTMO
Dividends and buybacks
Dividend yield–0.3%
Dividend per share, 12 months–$1.84
Dividend growth a year, past–+14.3%over 5 years
Buyback yield–1.2%
Shareholder yield–1.4%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: STLN or TMO

Didn't find what you were looking for?

Ask us
Which is bigger, Starling Oncology or Thermo Fisher Scientific?

By market value, Thermo Fisher Scientific ($260B) is about 751.9 times Starling Oncology ($346M), at today's prices.

How did STLN and TMO stock do over the last 5 years?

Since November 12, 2021, STLN's price moved -68.1% and TMO's +10.2%. With dividends: STLN -68.1% (-20.4% a year), TMO +11.8% (+2.3% a year). Past returns do not predict future ones.

Which pays the higher dividend, STLN or TMO?

The dividend yield at today's price is none for Starling Oncology and 0.26% for Thermo Fisher Scientific. Over the last twelve months they paid – and $1.84 per share.

Which has the higher profit margins, Starling Oncology or Thermo Fisher Scientific?

Over the last twelve months, the net margin was -5.7% for Starling Oncology and 14.9% for Thermo Fisher Scientific, and the operating margin -3.4% and 17.9%. Revenue was $620M and $47.4B.

Which is the better investment, Starling Oncology or Thermo Fisher Scientific?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.